Caphosol

Myeloma

M.D. Anderson Cancer CenterPhase 2Dormant

C

36/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 21/ 100
Competitive Position: 89/ 100

Competitive context

498 Active assets in the Myeloma cohort.

Asset / Sponsor	Phase	Rating
FILGRASTIM Jonsson Comprehensive Cancer Center	Phase 4	BBB
Inno-206 University of Arkansas	Phase 3	BBB
Hyaluronidase fihj Massachusetts General Hospital	Phase 4	BBB
Busulphan M.D. Anderson Cancer Center	Phase 4	BBB
Filanesib PETHEMA Foundation	Phase 2	BBB

View all 50 →

Same molecule, other indications

Caphosol is also rated in:

lymphomaDormant

CC

Indicative ·

41 / 100

cancerDormant

C

Indicative ·

35 / 100

small cell lung carcinomaDormant

D

Indicative ·

21 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.